← Back to Search

Amino Acid Formulation

Neuron012703 for Diabetic Neuropathy (Neuron012703 Trial)

Phase 2
Waitlist Available
Led By Gabriel Halperin, DPM
Research Sponsored by Targeted Medical Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights

Summary

A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.

Eligible Conditions
  • Neuropathy
  • Diabetic Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
VAS
Secondary outcome measures
NTSS-6
Routine Blood Panel

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neuron012703Experimental Treatment1 Intervention
Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.

Find a Location

Who is running the clinical trial?

Targeted Medical PharmaLead Sponsor
7 Previous Clinical Trials
434 Total Patients Enrolled
Gabriel Halperin, DPMPrincipal InvestigatorGabriel Halperin DPM Inc.
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top